Functional assays as prismatic views of drug activity: Relevance to new drug discovery

Journal of Receptors and Signal Transduction

Volumn 28, Issue 1-2, 2008, Pages 109-125

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

GPCR signaling; New drug discovery; Pathway analysis; Receptor theory

Indexed keywords

ANTIVIRUS AGENT; APLAVIROC; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE; HERBACEOUS AGENT; LP 1805; MARAVIROC; MEMBRANE PROTEIN; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; PROPRANOLOL; RECEPTOR PROTEIN; UK 427 857; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG ACTIVITY; DRUG DETERMINATION; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL MODEL; PROTEIN CONFORMATION; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; PHARMACOLOGY; RECEPTORS, CCR5; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 42549157192     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890801946318     Document Type: Review

References (62)

1. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonistspecific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 1980, 255, 7108-7117.
2. 2-adrenergic receptor: Extending the ternary complex model. J Biol Chem 1993, 268, 4625-4636.
3. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model. I. Model description. J Theor Biol 1996, 178, 151-167.
4. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity J Theor Biol1996, 178, 169-182.
5. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. J Theor Biol 1996, 181, 381-397.
6. Fraunfelder H, Parak F, Young RD. Conformational substrates in proteins. Annu Rev Biophys Biophys Chem 1988, 17, 451-479.
7. Fraunfelder H, Sligar SG, Wolynes PG. The energy landscapes and motions of proteins. Science 1991, 254, 1598-1603.
8. Onaran HO, Costa T. Agonist efficacy and allosteric models of receptor action. Ann NY Acad Sci 1997, 812, 98-115.
9. Onaran HO, Scheer A, Cotecchia S, Costa T A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor. In: Kenakin TP, Angus JA, Eds. The Pharmacology of Functional, Biochemical, and Recombinant Systems Handbook of Experimental Pharmacology, Vol. 148. Germany, Springer, Heidelberg, 2000, 217-280.
10. Burgen ASV Conformational changes and drug action. Fed Proc 1966, 40, 2723-2728.
11. Kenakin TP. Efficacy at G protein coupled receptors. Annu Rev Pharmacol Toxicol 2002, 42, 349-379..
12. Kenakin T.P. Efficacy at G protein coupled receptors. Nat Rev (Drug Discovery) 2002, 1, 103-109.
13. Rees S, Morrow D, Kenakin T. GPCR drug discovery through the exploitation of allosteric drug binding sites. Recept Chann 2002, 8, 261-268.
14. Black JW, Leff P Operational models of pharmacological agonist. Proc R Soc Lond. [Biol], 1983, 220, 141-162.
15. Kenakin T P. Predicting therapeutic value in the lead optimization phase of drug discovery. Nat Rev Drug Discovery 2003, 2, 429-437.
16. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M. β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G-protein-coupled receptors. Proc Natl Acad Sci USA 2003, 100, 11406-11411.
17. 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 2003, 64, 1357-1369.
18. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006, 70, 1575-1584.
19. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discovery 2006, 5, 730-739.
20. Costa T, Herz A. Antagonists with negative intrinsic activity at β-opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 1989, 86, 7321-7325.
21. 2-adrenergic receptor. J Biol Chem 1995, 270, 28268-28275.
22. Kenakin TP. Ligand-selective receptor conformations revisited: The promise and the problem. Trends Pharmacol. Sci. 2003, 24, 346-354.
23. Kenakin TP. Collateral efficacy in drug discovery: Taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 2007, 28, 407-415.
24. Urban JD, Clarke WP, Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320, 1-13.
25. Limbird L. The receptor concept: A continuing evolution. Mol Interv 2004, 4, 326-336.
26. Horne WC, Shyu J-F, Chakraborty M, Baron R. Signal transduction by calcitonin: Multiple ligands, receptors, and signaling pathways. Trends Endocrinol Metab 1994, 5, 395-401.
27. Watson C, Chen G, Irving PE, Way J, Chen W-J, Kenakin TP. The use of stimulus-biased assay systems to detect agonist-specific receptor active states: Implications for the trafficking of receptor stimulus by agonists. Mol. Pharmacol.2000, 58, 1230-1238.
28. Kenakin TP. New concepts in drug discovery: Collateral efficacy and permissive antagonism. Nat Rev Drug Discovery 2005, 4, 919-927.
29. Kenakin TP. Efficacy at G protein coupled receptors. Annu Rev Pharmacol Toxicol 2002, 42, 349-379.
30. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, et al. Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 2006, 281, 10856-10864.
31. Maillet EL, Pellegrini N, Valant C, Bucher B, Hibert MB, Bourguignon J-J, Glazi J-L. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J 2007, 21, 2124-2134.
32. Sachpatzidis A, Benton BK, Manfredi JP, Wang H, Hamilton A, Dohlman HG Loliset E. Identification of allosteric peptide agonists. J Biol Chem 2003, 278, 896-907.
33. Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, Kosteniset E. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2 Mol Pharmacol 2005, 68, 393-402.
34. Doranz BJ, Lu ZH, Rucker J, Zhang TY, Sharron M, Cen YH, Wang ZH, Guo HH, Du JG, Accavitti MA, Doms RW, Peiper SC. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997, 71, 6305-6314.
35. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, YiY. Margulies B, Collman RG, Doranz BJ, Parmentier M, Doms RW. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 1997, 71, 8999-9007.
36. Picard L, Simmons G, Power CA, Meyer A, Weiss RA, Clapham PR. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol 1997, 71, 5003-5011.
37. Doms RW, Peiper SC. Unwelcomed guests with master keys: How HIV uses chemokine receptors for cellular entry. Virology 1997, 235, 179-190.
38. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 1999, 274, 9617-9626.
39. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, Goldsmith MA. Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines. Science 1996, 274, 1924-1926.
40. Smyth RJ, Yi Y, Singh A, Collman RG. Determinants of entry cofactor utilization and Tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J Virol 1998, 72, 4478-4484.
41. Bieniasz PD, Fridell RA, Aramori I, Ferguson SSG, Caron MG, Cullen BR. HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J 1997, 16, 2599-2609.
42. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J,. Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393, 648-659.
43. Kazmierski W, Peckham JP, Duan M, Kenakin TP, Jenkinson S, Gudmundsson KS, Piscitelli SC, Feldman PL. Recent progress in discovery of new CCR5 and CXCR4 chemokine receptor antagonists as inhibitors of HIV-1 entry. Part 2. Curr Med Chem Anti-Infective Agents 2005, 4, 2456-2472.
44. Kazmierski WM, Kenakin TP, Gudmundsson KS. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Chem Biol Drug Dis 2006, 67, 13-26.
45. Domingo E, Menendez-Arias L, Quinones-Mateu ME, Holguin A, GutierrezRivas M, Martinez MA, Quer J, Novella IS, Holland JJ. Viral quasispecies and the problem of vaccine-escape and drug resistant mutants. Prog Drug Res 1997, 48, 99-128.
46. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidoviudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998, 72, 3773-3778.
47. Schols D, Este JA, Cabrera C, De Clercq E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1-α contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Virol. 1998, 72, 4032-4037.
48. Mosier ME, MoGastón DE, Picchio R, Gulizia RJ, Sabbe R, Poignard P, Picard L, Offord RE, Thompson DA, Wilken J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999, 73, 3544-3550.
49. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002, 99, 395-400.
50. Kenakin TP, Jenkinson S, Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 2006, 319, 710-723.
51. Jakubic J, Bacakova L, Lisa V, El-Fakahany EE, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997, 52, 172-179.
52. Xiang J, George SL, Wünschmann S, Chang Q, Klinzman D, Stapleton JT. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MlP-lα, MIP-1β, and SDF-1. Lancet 2004, 363, 2040-2046.
53. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL, Gallo RC. Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999, 96, 11986-11991.
54. 1 cycle arrest in T lymphocytes results in increased extracellular levels of β-chemokines: A strategy to inhibit R5 HIV-1. Proc Natl. Acad. Sci USA 2003, 100, 4179-4184.
55. Ullum H, Cozzi Lepri AC, Victor J, Aladdin H, Phillips AN, Gerstoft J, Skinho P-J, Pedersen BK. Production of β-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1β are associated with a decreased risk of HIV disease progression. J Infect Dis 1998, 177, 331-337.
56. Lori F, Jessen H, Foli A, Lisziewicz J, Matteo PS. Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA 1997, 277, 1437-1438.
57. Rogez C, Martin M, Dereuddre-Bosquet N, Martal J, Dormont D, Clayette P. Anti-human immunodeficiency virus activity of tau interferon in human macrophages: Involvement of cellular factors and β-chemokines. J Virol 2003, 77, 12914-12920.
58. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'Connell RJ, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ, Ahuja SK. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005, 310, 1434-1440.
59. Choi W-T, Kaul M, Kumar S, Wang J, Krishna Kumar IM, Dong C-Z, An J, Lipton SA, Huang Z. Neuronal apoptotic signaling pathways probed and intervened by synthetically and modularly modified (SMM) chemokines. J Biol Chem 2007, 282, 7154-7163.
60. Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999, 96, 8212-8216.
61. Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O-Sullivan MP, Walter MJ, Schwendener RA, Cook DN, Danoff TM, Holtzman MJ. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nature Med 2005, 11, 1180-1187.
62. Vhlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vhlahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic singaling pathways. J Immunol 2002, 169, 5546-5554.